耐性高血圧におけるエンドセリンのABCDからEへ
George R Abraham1, Anthony P Davenport2
1Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Cell
|January 5, 2023
まとめ
血管収縮剤であるエンドセリン-1は 血管のトーンを調節する. 耐性高血圧の治療において,エンドセリン受容体抗薬は有望であり,臨床の新たな時代を象徴する可能性がある.
科学分野:
- 心血管薬学
- 高血圧 研究
背景:
- エンドセリン-1は,血管のトーンを調節する強力な血管圧縮ペプチドです.
- エンドセリン- 1経路の薬理学的阻害は,確立された臨床応用が限られている.
- 耐性高血圧は依然として重要な臨床的課題です.
研究 の 目的:
- 耐性高血圧患者におけるエンドセリン受容体抗体の有効性を評価する.
- 高血圧管理のためのエンドセリン-1経路の標的化の可能性を調査する.
主な方法:
- エンドセリン受容体アンタゴニストを調査した最近の臨床試験を分析した.
- この研究は,治療に抵抗する高血圧の患者に焦点を当てた.
主要な成果:
- 臨床試験では,エンドセリン受容体の抗体が新たな役割を果たす可能性があることが示されました.
- これらの抗薬は,耐性高血圧の管理に有効である可能性が示唆されています.
結論:
- 耐性高血圧の治療において,エンドセリン受容体抗薬が主流の臨床療法に移行する可能性がある.
- エンドセリン1経路をターゲットにすることは 有望な治療戦略です
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
215
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
753
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
753
Antihypertensive Drugs: Angiotensin II Receptor Blockers
808
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
808
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Hypertension II: Pathophysiology
34
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
34
Antihypertensive Drugs: Direct Renin Inhibitors
731
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
731


